Difference between revisions of "Sonidegib (Odomzo)"
Warner-admin (talk | contribs) m (Text replacement - "[[Category:Drugs FDA" to "[[Category:FDA") |
Warner-admin (talk | contribs) m (Text replacement - "Basal cell carcinoma (BCC)" to "Cutaneous basal cell carcinoma") |
||
| Line 7: | Line 7: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| − | *[[ | + | *[[Cutaneous basal cell carcinoma]] |
==Patient drug information== | ==Patient drug information== | ||
| Line 29: | Line 29: | ||
[[Category:SMO inhibitors]] | [[Category:SMO inhibitors]] | ||
| − | [[Category: | + | [[Category:Cutaneous basal cell carcinoma medications]] |
[[Category:FDA approved in 2015]] | [[Category:FDA approved in 2015]] | ||
Revision as of 19:22, 16 August 2018
General information
Class/mechanism: Hedgehog pathway inhibitor. Sonidegib binds to and inhibits the transmembrane protein Smoothened (SMO), which is part of the Hedgehog signal transduction pathway that is clinically relevant in diseases such as basal cell cancer.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
History of changes in FDA indication
- 7/24/2015: Initial FDA approval "for the treatment of patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy."[1]
Also known as
- Code name: LDE225
- Generic name: erismodegib
- Brand name: Odomzo